Apotheca Biosciences, Inc. Stock

CBDC

US03836L1070

Biotechnology & Medical Research

OTC Markets Traded

Latest news : Apotheca Biosciences, Inc.

20-06-19	Apotheca Biosciences, Inc. cancelled the acquisition of 51% of Hemp Bloom LLC.	CI
19-08-09	Apotheca Biosciences, Inc. Announces Resignation of P.C. Sundareswaran as the Chairman and CEO	CI
19-07-02	Deirdre Fernandes Resigns as VP of Operations and Director of Apotheca Biosciences, Inc	CI
19-06-20	Apotheca Biosciences, Inc. signed a definitive agreement to acquire 51% of Hemp Bloom LLC.	CI
19-06-19	Apotheca Biosciences, Inc. Reports Earnings Results for the First Quarter Ended April 30, 2019	CI
19-06-18	Apotheca Biosciences Introduces XKAPE by ProMED, Newest Product Line Designed for Independent Grocers & Convenience Stores	CI
19-05-31	Apotheca Biosciences, Inc. Announces Resignation of Verghese from Chief Technical Officer and Director	CI
19-04-04	Apotheca Biosciences, Inc. will Change its Ticker to CBDC from PCFP	CI
19-04-01	Apotheca Biosciences Announces the Incorporation of Its Newly Created Subsidiary ProMED Biosciences, Inc	CI
19-02-06	Apotheca Biosciences, Inc. Appoints P.C. Sundar as its Chairman & CEO	CI
19-01-15	Apotheca Biosciences Introduces ProMED	CI
18-12-12	Apotheca Biosciences, Inc. Announces Management Changes	CI
18-11-06	Apotheca Biosciences Signs an LOI For Purchase of Nano Creaciones S.A. P.I. de C.V	CI

More news

Press Releases: Apotheca Biosciences, Inc.

19-06-18	Apotheca Biosciences (CBDC) Introduces XKAPE by ProMED, Our Newest Product Line Designed for Independent Grocers & Convenience Stores -- Wellness to Go	GL
19-05-21	Apotheca Biosciences’ (CBDC) Distribution of ProMED’s Pharma Grade CBD Products Receives Great Response -- Company in Discussion with Wholesalers for Mass Distribution of ProMED CBD Product Lines for an Initial 500 Outlets Nationally	GL

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APOTHECA BIOSCIENCES, INC.	-.--%	-.--%	-	-	36.32K
LONZA GROUP AG	+0.68%	-2.28%	+1.91%	+19.70%	48.42B
REVOLUTION MEDICINES, INC.	+5.63%	+4.01%	+490.60%	+634.98%	43.66B
BEONE MEDICINES AG	+4.09%	+0.38%	+12.85%	+87.41%	39.51B
IQVIA HOLDINGS INC.	+1.99%	-0.67%	+24.85%	+12.22%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+58.18%	32.61B
ASCENDIS PHARMA A/S	-0.24%	-2.71%	-	-	16.32B
MEDPACE HOLDINGS, INC.	+2.48%	-1.59%	+28.08%	+133.79%	16.15B
EUROFINS SCIENTIFIC SE	-0.62%	-0.06%	+3.95%	+27.74%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.88%	+3.39%	+82.44%	+43.29%	13.37B
Average	+1.57%	-0.35%	+83.16%	+127.16%	29.24B
Weighted average by Cap.	+2.13%	-0.62%	+102.39%	+152.48%

See all sector performances

Apotheca Biosciences, Inc., formerly Cannabis Leaf Inc., is a medical device company. The Company is developing engineering and device solutions for cannabinoid medical technologies. It is focused on developing medical products and nutraceuticals and formulates and delivers technologies. The Company serves healthcare and consumer care industry. The Company's products include transdermal and sublingual. It also provides nasal delivery technologies for precise and controlled dosing of cannabinoids. Its pipeline products includes, transdermal, sublingual, and nasal delivery technologies.

Employees

Sector

Biotechnology & Medical Research

More about the company